Thyroid Cancer: Imaging Techniques (Nuclear Medicine)

Similar documents
PEDIATRIC Ariel Katz MD

Calcitonin. 1

Thyroid Cancer. With 51 Figures and 30 Tables. Springer

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

Adjuvant therapy for thyroid cancer

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

Evaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada

Index. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans

PET/CT Frequently Asked Questions

Reoperative central neck surgery

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Approach to Thyroid Nodules

Imaging in Pediatric Thyroid disorders: US and Radionuclide imaging. Deepa R Biyyam, MD Attending Pediatric Radiologist

Thyroid Cancer (Carcinoma)

Nuclear Medicine in Oncology

B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.

Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer

PET/CT in lung cancer

Radiology Pathology Conference

Outcomes Report: Accountability Measures and Quality Improvements

What you need to know about Thyroid Cancer

Anca M. Avram, M.D. Professor of Radiology

Outcomes Report: Accountability Measures and Quality Improvements

F NaF PET/CT in the Evaluation of Skeletal Malignancy

Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.

Thyroid Cancer: Overview And Peculiar Aspects In Philippines Nemencio A. Nicodemus Jr., MD

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD

Clinical indications for positron emission tomography

WTC 2013 Panel Discussion: Minimal disease

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA

Risk Adapted Follow-Up

Cancer A Superficial Introduction

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Mandana Moosavi 1 and Stuart Kreisman Background

A rare case of solitary toxic nodule in a 3yr old female child a case report

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

Dynamic Risk Stratification:

Imaging in Thyroid Cancer

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

THYROID CANCER IN CHILDREN

Differentiated Thyroid Cancer: Initial Management

AN INTRODUCTION TO NUCLEAR MEDICINE

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Pitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD

Preoperative Evaluation

Medullary Thyroid Carcinoma. This case was provided by Treant Hospital, Bethesda, Hoogeveen, The Netherlands

An Unexpected Cause of Hypoglycemia

Epidemiology in Texas 2006 Annual Report. Cancer

Pathology of the Thyroid

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

Differentiated Thyroid Carcinoma

New Visions in PET: Surgical Decision Making and PET/CT

Oncology 101. Cancer Basics

Subject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:

Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination

Volume 2 Issue ISSN

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events

Work Up & Evaluation of Thyroid Nodules In 2013: State of The Art

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

Case-Based Discussion of Thyroid Cancer Therapy

Thyroid Nodules. Family Medicine Refresher Course Geeta Lal MD, FACS April 2, No financial disclosures

Persistent & Recurrent Differentiated Thyroid Cancer

Case Scenario 1: Thyroid

1. Protocol Summary Summary of Trial Design. IoN

Bioengineering and World Health. Lecture Twelve

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

Principal Site Investigator ENHANCE (Evaluation of Thyroid FNA Genomic Signature) study: An IRB approved study with funding to Rochester Regional

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

FDG PET/CT in the Detection of Pancreatic Metastasis in a Patient with Follicular Thyroid Carcinoma and Negative I-131 Whole Body Scan Findings

Thyroid Neoplasm. ORL-Head and neck Surgery 2014

Cancer in Estonia 2014

Cancer Program Report 2014

Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis

Radiology Pathology Conference

Reference No: Author(s) Approval date: October committee. September Operational Date: Review:

Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Thyroid Ultrasonography: clinical and radiological correlations

Case 5: Thyroid cancer in 42 yr-old woman with Graves disease

B Berry, J. 25 see also suspensory ligament of Berry biopsy see fine-needle aspiration biopsy (FNAB); open wedge biopsy

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Carcinoma of thyroid - clinical presentation and outcome

Thyroid nodules 3/22/2011. Most thyroid nodules are benign. Thyroid nodules: differential diagnosis

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Transcription:

Thyroid Cancer: Imaging Techniques (Nuclear Medicine) Andrei Iagaru, MD MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Introduction Ø There are approximately 56,460 new cases of thyroid carcinoma annually in the United States, and the overall incidence continues to rise Ø Women are more likely to have thyroid cancer at a ratio of 3:1 Ø Thyroid cancer can occur in any age group, although it is most common after age 30 and its aggressiveness increases significantly in older patients Jemal A, et al. Cancer statistics, 2012. CA Cancer J Clin. 2012 62:10-29. MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Incidence of thyroid cancer 25000 Thyroid cancer cases and deaths >56,460 in 2012 20000 15000 10000 5000 0 1 2 3 4 5 6 7 8 1970 1975 1980 1985 1990 1995 2000 2003 Total cases, women, men: Total deaths, women, men Deaths MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

2012 Estimated US Cancer Cases* Men 766,860 Women 678,060 Prostate 29% Lung & bronchus 14% Colon & rectum 9% Urinary bladder 7% Melanoma of skin 5% Kidney 5% Non-Hodgkin 4% lymphoma Oral cavity 3% Leukemia 3% Pancreas 3% 29% Breast 14% Lung & bronchus 9% Colon & rectum 6% Uterine corpus 5% Thyroid 4% Non-Hodgkin lymphoma 4% Melanoma of skin 3% Ovary 3% Kidney 3% Pancreas Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

2012 Estimated US Cancer Deaths* Lung & bronchus 29% Colon & rectum 9% Prostate 9% Pancreas 6% Leukemia 5% Liver & bile duct 4% Esophagus 4% Non-Hodgkin 4% lymphoma Urinary bladder 3% Kidney 3% Men 289,550 Women 270,100 26% Lung & bronchus 14% Breast 9% Colon & rectum 7% Pancreas 6% Ovary 4% Leukemia 3% Non-Hodgkin lymphoma 3% Uterine corpus 2% Liver and bile duct 2% Brain/ONS Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Thyroid cancer: ethnic influence " 3.3/100,000 " 6.2/100,000 " 6.5/100,000 " 9.1/100,000 " 10.5/100,000 " 14.6/100,000 " 32.5/100,000 " African American women " Hispanic women " White women " Hawaiian women " Vietnamese women " Filipino women " Filipino women 55-69 yrs MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø Papillary thyroid cancer (PTC) is the most common of all thyroid cancers, comprising approximately 70-75% of follicular cell derived cancers Ø Papillary cancer can occur in any age group, although its peak incidence in the fourth and fifth decades of life Ø It is more common in women than in men (2.5:1) MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø The main risk factors for the development of PTC include a history of childhood head and neck radiation for benign conditions, or a family history of papillary cancer Ø PTC typically has an excellent prognosis, with overall 10- year survival rates estimated at 80-90% Ø Age over 45 years at time of diagnosis, tumor size over 4 cm, extrathyroidal extension of tumor, lymph node recurrence, and distant metastases negatively influence survival MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

PTC: FNA shows large cells and nuclei, and their cytoplasm has a ground glass appearance. Nucleoli are prominent and the nuclei have clefts, gooves and holes due to intranuclear cytoplasmic inclusions. 2005 UpToDate

PTC: Surgical specimen showing the classical histologic appearance of papillary cancer, with papillary structure and no folicles or colloid. 2005 UpToDate

Ø Unlike papillary and follicular thyroid cancers, which arise from thyroid hormone producing cells, medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland Ø A characteristic feature of this tumor is the production of calcitonin Ø The C cells originate from the embryonic neural crest; as a result, medullary carcinomas often have the clinical and histologic features of other neuroendocrine tumors such as carcinoid and islet-cell tumors MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø MTC constitutes about 5-10% of all thyroid malignancies Ø Most medullary thyroid carcinomas are sporadic. However, some are familial as part of the multiple endocrine neoplasia type 2 (MEN2) syndrome Ø Overall 10-year survival rates are 90% when all the disease is confined to the thyroid gland, 70% with spread to cervical lymph nodes, and 20% when spread to distant sites is present MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

MTC: FNA with immunostaining for calcitonin reveals nuclei of the tumor cells placed eccentrically, larger and more pleomorphic than those of normal follicular cells. Immunocytologic staining for calcitonin is positive. The background contains many RBC s that nonspecifically take up the stain. 2005 UpToDate

MTC: Surgical specimen showing typical histologic appearance of medullary carcinoma. 2005 UpToDate

Imaging PTC

Colloid Tg Thyroperoxidase I - Tg Pendrin I-Tg L Capillary Tg Synthesis I - I - I - I - I - NIS Na + I - T4, T3 MIT, DIT T4, T3 Lysosomal Digestion

Diagnostic whole body 123 I scan Ø Proof of elevated TSH ü How high should it be? ü Withdrawal of thyroid hormone ü rhtsh Ø Measurement of Tg when TSH is stimulated Ø Low iodine diet Ø Which radionuclide of iodine? MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

How high should TSH be? Ø 25 mu/l Ø 30 mu/l Ø 50 mu/l Ø In one of our published reports the mean TSH value was 121 mu/l ATA Management Guidelines: TSH > 30 mu/l Rating B MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Withdrawal of thyroid hormone vs. rhtsh ü 4-6 week delay before testing and treatment ü Physical symptoms and signs of hypothyroidism ü Psychological symptoms of hypothyroidism ü 2 week delay for testing and treatment ü No signs and symptoms of hypothyroidism MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Thyroglobulin Ø Tg values depend on amount of thyroid tissue present Ø Tg levels increase with increase in TSH Ø About 25% of patients with papillary cancer have antibodies to Tg ü Antibodies alter validity of measurement ü Antibodies probably benefit prognosis ATA recommendation: Tg measured every 6-12 months using IRMA (same laboratory with antibody assay) Rating A MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Day 13 of low iodine diet Christmas card from patient, presented with permission ATA recommendation: Lowiodine diet for 1-2 weeks Rating B Courtesy of Dr McDougall

123 I/ 131 I: false positive scans Carlisle, Lu and McDougall Nucl Med Comm 2003;24:715-735 Shapiro et al in Thyroid Cancer edited by Wartofsky and Van Nostrand Humana Press 2006, Chap 16 Unusual sites of Iodine uptake Tissues that have NIS receptor Secretion and excretion of iodine Other pathologies Breast Thymus Salivary glands Courtesy of Dr McDougall

123 I/ 131 I: false positive scans Unusual sites of Iodine uptake Tissues with NIS receptor Secretion and excretion of iodine Other pathologies Saliva Milk Gastric fluid Bile/stool Sweat Courtesy of Dr McDougall

Pre-therapy Post-therapy

131 I trapping in thymus is uncommon, but not rare! Davidson and McDougall Nucl Med Comm 2000;27:425-430

123 I/ 131 I: false negative scans

124 I PET/CT in DTC

Ø 52 women, 17 men; 17-83 years old (average: 46) Ø 124 I PET/CT and a whole body scan were done, before and after 131 I ablation, respectively Ø 124 I PET/CT and 131 I WBS matched in 58/67 patients (86.6%) Ø 124 I PET/CT detected more disease than 131 I WBS in 5/67 patients (7.5%), mainly lymph node involvement Ø 131 I WBS detected more disease than 124 I PET/CT in 4/67 patients (4.9%), including lymph nodes and disseminated 131 I-avid lung metastases MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø 39 women, 31 men; 12-83 years old (average: 50) Ø 124 I PET/CT and a whole body scan were done, before and after 131 I ablation, respectively Ø Quantitative data consisted of absolute lung 124 I activity concentrations and lung-to-background (L/B) 124 I uptake ratios Ø Only 1/7 patients with disseminated lung metastases on the 131 I WBS had visible disseminated lung uptake on the 124 I PET/CT Ø L/B ratios overlapped between the subjects with/without 124 I uptake in disseminated lung metastases to an extent that an unequivocal diagnosis based solely on this criterion was impossible in some patients MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø Some differentiated thyroid cancers lose the ability to trap iodine Ø How would you determine extent of disease in this situation? MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Normal thyroid: little or no uptake of 18 F FDG MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Diffusely increased uptake in the thyroid MIPS Diffuse uptake most likely chronic lymphocytic thyroiditis 18 F FDG PET in 1,102 healthy subjects Diffuse uptake in the thyroid in 36 patients 33 women 27 positive thyroid antibodies Ultrasound consistent with chronic thyroiditis or with Graves disease if the patient is thyrotoxic Molecular Imaging Program at Stanford Yasuda et al. Radiology 1998;207:775-8 Stanford University School of Medicine Department of Radiology

123 I scan positive; Tg 1,000 ng/ml PET very positive; surgery and XRT

63-year-old woman with follicular thyroid cancer. Whole body 123 I scintiscan is negative. FDG PET/CT shows multiple lung metastases.

57-year-old man with papillary thyroid cancer. 123 I scintigraphy and FDG PET/CT show lesions in the thyroid bed (arrows), mediastinal lymph nodes (black arrowheads) and the left hip (white arrowheads).

123 I scan positive; Tg >3,000 ng/ml PET very positive; surgery and XRT

Ø 18 F FDG PET/CT is commonly used when there is discordance between elevated Tg and negative 123 I wholebody scans (WBS) Ø When used in combination, 18 F FDG PET/CT and 123 I WBS may result in tumor foci being missed in as few as 7% of cases, suggesting a complementary role for the two imaging modalities MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø 14 women & 7 men, 26-75 years old (average: 50 ± 16) Ø All patients had papillary cancer MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Serum Tg levels were 1.0-10.0 ng/ml (average: 4.5 ng/ml) in the patients with negative PET scans (white) and 1.0-38.0 ng/ml (average: 16.8 ng/ml) in the patients with positive scans (black) P: 0.029

Local thyroid cancer recurrence, as well as pulmonary metastases in a 75-year old woman with Tg=36 ng/ml.

Ø The sensitivity and specificity of 18 F FDG PET for disease detection in this cohort were 88.2% (95% CI: 65.7-96.7) and 75% (95 % CI: 30.1-95.4), respectively Ø Detectable levels of Tg, even in the presence of a negative 123 I WBS or anatomic imaging, should prompt imaging with 18 F FDG PET/CT Ø Tg values less than 10 ng/ml can produce both positive and negative PET scans, while levels higher than 10 ng/ml appear to correlate with successful tumor identification on PET scans MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø 44 women & 32 men, 20-81 years old (average: 51.1±18.1) Ø 68 patients had papillary and 8 had follicular cancer Ø 98 PET/CT scans were analyzed (59 patients had 1 scan, 12 patients had 2 scans and 5 patients had 3 scans) MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Sensitivities and specificities of PET/CT in differentiated thyroid cancer Sensitivity % (95% CI) Specificity % (95% CI) Based on patients (n=76) 88.6 (78.8-94.3) 89.3 (71.9-97.1) Lesions in thyroid bed 87.5 (73.4-95.1) 96.5 (87.6-99.7) Metastases (overall) 88.9 (78.5-94.8) 94.3 (80.4-99.4) Lymph nodes metastases 87.7 (76.4-94.2) 97.1 (83.8-99.9) Other metastases 88.9 (65.9-98.1) 96.4 (80.8-99.9) MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Positive PET/CT Negative PET/CT Tg ng/ml mean (range) 1203 (0.5-28,357) 9.7 (0.5-123) SUV max (thyroid bed) 10.8 (2.5-32) SUV max (metastases) 7.53 (2.5-26.2) P value: 0.0114 TSH miu/l mean (range) in 73 scans 51 (<0.01-262) 32 (0.01-225) ü Tg levels ranged 0.5-123.0 ng/ml (average: 9.72) in pts with negative PET/CT and 0.5-28,357 ng/ml (average: 1203) for those with positive PET/CT scans (P value: 0.0389) ü TSH values ranged 0.01-225 miu/l (average: 32.21) in pts with negative PET/CT and 0.004-262 miu/l (average: 51.22) in pts with positive scans (P value: MIPS 0.258) Stanford University Molecular Imaging Program at Stanford School of Medicine Department of Radiology

Ø 38 women, 25 men; 25-77 years old (average: 52) Ø PET/CT was performed before (basal PET) and 24-48 h after rhtsh administration (rhtsh-pet) in 63 patients (52 PTC and 11 FTC) Ø rhtsh-pet was significantly more sensitive than basal PET for the detection of lesions (95 vs. 81%; P = 0.001) and tended to be more sensitive for the detection of involved organs (94 vs. 79%; P = 0.054) Ø However, basal PET and rhtsh-pet did not have significantly different sensitivity for detecting patients with any lesions (49 vs. 54%; P = 0.42) Ø Treatment changes due to true positive lesions occurred in 6% of cases MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Imaging MTC

Ø When MTC is diagnosed by fine needle aspiration biopsy, ultrasonography, CT and/or MRI scanning of the neck are indicated to look for cervical lymph node involvement Ø 123 I MIBG, 111 In Octreotide, and 99m Tc DMSA-V were investigated for evaluation of MTC and are currently used in detection of metastatic/recurrent disease Ø 18 F FDG PET detects more lesions than 99m Tc DMSA-V and 111 In Octreotide, as well as bone scintigraphy combined with morphologic imaging such as ultrasound, CT, or MRI MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Ø 7 women & 6 men, 15-62 years old (average: 48 ± 13) Ø All patients had histologic diagnosis of MTC Ø The PET scan request was triggered by rising levels of calcitonin and negative anatomical imaging studies MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

The calcitonin levels ranged from 52 to 5090 pg/ml (average: 1996 pg/ml) in patients with negative PET scans (black) and from 132 to 9500 pg/ml (average: 3757 pg/ml) in patients with positive studies (gray) P: 0.26

Whole body FDG PET of a 49-year old female with MTC recurrence in the thyroid bed and superior mediastinum. Her calcitonin levels prior to the PET examination were 9500 pg/ml.

Negative scan of a 42-year old female with calcitonin levels of 5090 pg/ml.

FDG PET scan of a 62-year old male with recurrent cervical (arrows) and hepatic disease (arrowheads), and calcitonin levels of 5290 pg/ml.

Ø The lesions were located in superior mediastinum (4), cervical lymph nodes (3), thyroid bed (2), lung (1) and liver (1) Ø The sensitivity and specificity of F-18 FDG PET for recurrence/residual disease detection in this cohort were 85.7% (95% CI: 48.7-97.4) and 83.3 % (95 % CI: 43.6-96.9), respectively Ø An overlap of measured calcitonin levels in patients with positive/negative scans was noted MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology

Imaging ATC

PET in anaplastic thyroid cancer Ø To stage disease Ø To define local extent of cancer Ø To evaluate response to therapy

Focal uptake of 18 FDG Scan done for non thyroidal cancer ü Incidentaloma ü Metaboloma Approximately 40-50% chance of thyroid cancer, usually papillary BUT Metastasis to thyroid can occur

THANK YOU! http://nuclearmedicine.stanford.edu http://mips.stanford.edu